A review of the assessment of dyskinesias

Movement Disorders

Volumn 14, Issue 5, 1999, Pages 737-743

  Hoff, Jorrit I ^a   Van Hilten, Bob J ^a   Roos, Raymund A C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Assessment; Dyskinesias; Huntington's disease; Parkinson's disease; Tardive dyskinesia

Indexed keywords

LEVODOPA; NEUROLEPTIC AGENT;

ACCELEROMETER; CIRCADIAN RHYTHM; DISEASE SEVERITY; DYSKINESIA; HUMAN; HUNTINGTON CHOREA; LONG TERM CARE; METHODOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; RELIABILITY; REVIEW; STRESS;

DYSKINESIAS; ELECTROMYOGRAPHY; HUMANS; HUNTINGTON DISEASE; REPRODUCIBILITY OF RESULTS;

EID: 0032757531     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(199909)14:5<737::AID-MDS1005>3.0.CO;2-A     Document Type: Review

References (69)

1. Marsden CD, Parked JD, Quin NM. Fluctuations of disability in Parkinson's disease - clinical aspects. In: Marsden CD, Fahn S, eds. Movement Disorders. London: Butterworths Scientific, 1982: 96-122.
2. Soares KVS, McGrath JJ. Anticholinergic medication for neuroleptic induced tardive dyskinesia. In: Adams CE, Duggan L, de Jesus Mari J, White P, eds. Schizophrenia Module of the Cochrane Database of Systematic Reviews [updated June 2, 1997]. Available in The Cochrane Library [database on disk and CD-ROM]. The Cochrane Collaboration, Issue 3. Oxford: Update Software, 1997. Updated quarterly.
3. van Vugt JP, Siesling S, Vergeer M, van der Velde EA, Roos RA. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry 1997;63:35-39.
4. Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997;12:483-496.
5. Lang AE, Lozano AM, Montgomery E, Duff J, Tasker R, Hutchinson W. Posteroventral medial pallidotomy in advanced Parkinson's disease. N Engl J Med 1997;337:1036-1042.
6. Krack P, Limousin P, Benabid AL, Pollak P. Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease. Lancet 1997;350:1676.
7. Wang Y, Turnbull I, Calne S, Stoessl AJ, Calne DB. Pallidotomy for tardive dyskinesia. Lancet 1997;347:777-778.
8. Calne DB. Involuntary movements: an overview. In: Joseph AB, Young RR, eds. Movement Disorders in Neurology and Neuropsychiatry. Boston, MA: Blackwell Scientific Publications, 1992:1-2.
9. Siesling S, van Vugt JPP, Zwinderman AH, Kieburtz K, Roos RAC. Unified Huntington's Disease Rating Scale: a follow-up. Mov Disord 1998;13:915-919.
10. Marconi R, Lefebvre-Caparros D, Bonnet A, Vidailhet M, Dubois B, Agid Y, Levodopa-induced dyskinesias in Parkinson's disease: phenomenology and pathophysiology. Mov Disord 1994;9:2-12.
11. Brown KW, White T. The influence of topography on the cognitive and psychopathological effects of tardive dyskinesia. Am J Psychiatry 1992;149:1385-1389.
12. Gureje O. Topographic subtypes of tardive dyskinesia in schizophrenic patients aged less than 60 years: relationship to demographic, clinical, treatment, and neuropsychological variables. J Neurol Neurosurg Psychiatry 1988;51:1525-1530.
13. Wood PHN. Appreciating the consequences of disease: the international classification of impairments, disabilities, and handicaps. WHO Chronicle 1980;34:376-380.
14. Hobart JC, Lamping DL, Thompson AJ. Evaluating neurological outcome measures: the bare essentials. J Neurol Neurosurg Psychiatry 1996;60:127-130.
15. Golbe LI, Pae J. Validity of a mailed epidemiological questionnaire and physical self-assessment in Parkinson's disease. Mov Disord 1988;3:245-254.
16. Shoulson I, Goldblatt D, Charlton M, Joynt RJ. Huntington's disease: treatment with muscimol, a GABA-mimetic drug. Ann Neurol 1978;4:279-284.
17. Marsden CD, Schachter M. Assessment of extrapyramidal disorders. Br J Clin Pharmacol 1981;11:129-151.
18. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136-142.
19. de Boo G, Tibben A, Hermans J, Maat A, Roos RAC. Subtle involuntary movements are not reliable indicators of incipient Huntington's disease. Mov Disord 1998;13:96-99.
20. Fahn S, Elton RL. The Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease, vol 2. Florham Park, NJ: Macmillan Healthcare Information, 1987:153-163.
21. Larsen TA, Calne S, Calne DB. Assessment of Parkinson's disease. Clin Neuropharmacol 1984;7:165-169.
22. Montgomery GK, Reynolds NC Jr, Warren RM. Qualitative assessment of Parkinson's disease: study of reliability and data reduction with an abbreviated Columbia scale. Clin Neuropharmacol 1985;8:83-92.
23. Kurlan R, Rubin AJ, Miller C, Rivera-Calimlim L, Clarke C, Shoulson I. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 1986;20: 262-265.
24. Lieberman A, Dziatolowski M, Gopinathan G, Kupersmith M, Neophytides A, Korein J. In: Goldstein M, Calne DB, Lieberman A, Thorner MD, eds. Ergot Compounds and Brain Function. New York, NY: Raven Press, 1980:277-286.
25. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part II. Ann Neurol 1988;24:372-378.
26. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The 'on-off' phenomenon in Parkinson's disease. N Engl J Med 1984;310:483-488.
27. Teychenne PF, Pfeiffer RF, Bern SM, McInturff D, Calne DB. Comparison between lergotrile and bromocriptine in parkinsonism. Ann Neurol 1978;3:319-324.
28. Langston JW, Widner H, Goetz CG, et al. Core Assessment Program for Intracerebral Transplantation (CAPIT). Mov Disord 1992;7:2-13.
29. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intra-rater reliability assessment. Mov Disord 1994;9:390-394.
30. Caligiuri MP. Instrumental measurement of tardive dyskinesia. In: Yassa R, Nair NPV, Jeste DP, eds. Neuroleptic Induced Movement Disorders: A Comprehensive Survey. New York, NY: Cambridge University Press, 1997:241-256.
31. Simpson GM, Singh H. Tardive dyskinesia rating scales. L'Encephale 1988;14:175-182.
32. Gardos G, Cole JO, La Brie R. The assessment of tardive dyskinesia. Arch Gen Psychiatry 1977;34:1206-1212.
33. May PRA, Lee MA, Bacon RC. Quantitative assessment of neuroleptic-induced extrapyramidal symptoms: clinical and non-clinical approaches. Clin Neuropharmacol 1983;6(suppl 1): S35-S51.
34. Bostrom AC. Assessment scales for tardive dyskinesia. J Psychosoc Nurs Ment Health Serv 1988;26:9-12.
35. AIMS. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: United States Department of Health, Education, and Welfare, 1976:534-537.
36. Lane RD, Glazer WM, Hansen TE, Berman WH, Kramer SI. Assessment of tardive dyskinesia using the abnormal involuntary movement scale. J Nerv Ment Dis 1985;173:353-357.
37. Simpson GM, Lee JH, Zoubok B, Gardos G. A rating scale for tardive dyskinesia. Psychopharmacology 1979;64:171-179.
38. Sprague RL, Kalachnik JE, Breuning SE, et al. The dyskinesia identification system - Coldwater (DIS - Co): a tardive dyskinesia rating scale for the developmentally disabled. Psychopharmacol Bull 1984;20:328-338.
39. Sprague RL, Kalachnik JE. Reliability, validity, and a total cutoff score for the dyskinesia identification system: condensed user scale (DISCUS) with mentally ill and mentally retarded populations. Psychopharmacol Bull 1991;27:51-58.
40. Smith RC, Allen R, Gordon J, Wolff J. A rating scale for tardive dyskinesia and parkinsonian symptoms. Psychopharmacol Bull 1983;19:266-276.
41. Barnes TRE, Trauer T. Reliability and validity of a tardive dyskinesia videotape rating technique. Br J Psychiatry 1982;140:508-515.
42. Richardson MA, Craig TJ, Branchey MH. Intra-patient variability in the measurement of tardive dyskinesia. Psychopharmacology 1982;76:269-272.
43. Yanagisawa N, Nezu A. Pathophysiology of involuntary movements in Parkinson's disease. Eur Neurol 1987;26(suppl 1):30-40.
44. Yanagisawa N. EMG characteristics of involuntary movements. In: Bruyn GW, Buruma OJS, Roos RAC, eds. Dyskinesia. Proceedings of a Boerhaave Course and Japanese-Dutch workshop. Uden: Sandoz BV, 1984.
45. Bathien N, Rondot P, Koutlidis RM. Neurophysiologie clinique des dyskinesies tardives post-neuroleptiques et des dyskinesies dopa-induites de la maladie de Parkinson. J Physiol (Paris) 1981; 77:131-141.
46. Bathien N, Koutlidis RM, Rondot P. EMG patterns in abnormal involuntary movements induced by neuroleptics. J Neurol Neurosurg Psychiatry 1984;47:1002-1008.
47. Marsden CD, Obeso JA, Rothwell JC. Clinical neurophysiology of muscle jerks: myoclonus, chorea, and tics. In: Desmedt JE, ed. Motor Control Mechanisms in Health and Disease. New York, NY: Raven Press, 1983:865-881 (Adv Neurol, vol 39).
48. Marsden CD, Obeso JA, Rothwell JC. Clinical neurophysiology of muscle jerks: myoclonus, chorea, and tics. In: Desmedt JE, ed. Motor Control Mechanisms in Health and Disease. New York, NY: Raven Press, 1983:865-881 (Adv Neurol, vol 39).
49. Tan BK, Mastebroek HAK, Zaagman WH. Huntington's chorea. A random process. Clin Neurol Neurosurg 1976;79:215-221.
50. Yanagisawa N. The spectrum of motor disorders in Huntington's disease. Clin Neurol Neurosurg 1992;94(suppl):S182-S184.
51. Hallett M. Analysis of abnormal voluntary and involuntary movements with surface electromyography. In: Desmedt JE, ed. Motor Control Mechanisms in Health and Disease. New York, NY: Raven Press, 1983:907-914 (Adv Neurol, vol 39).
52. Hallett M. Analysis of abnormal voluntary and involuntary movements with surface electromyography. In: Desmedt JE, ed. Motor Control Mechanisms in Health and Disease. New York, NY: Raven Press, 1983:907-914 (Adv Neurol, vol 39).
53. Haines J, Sainsbury P. Ultrasound system for measuring patients' activity and disorders of movement. Lancet 1972;2:802-803.
54. Resek G, Haines J, Sainsbury P. An ultrasound technique for the assessment of tardive dyskinesia. Br J Psychiatry 1981;138:474-478.
55. Sainsbury P, Wood E. Measuring gesture: its cultural and clinical correlates. Psychol Med 1977;2:63-72.
56. McCleland HA, Fairbairn AF, McDonald M, Nicholas TRM, Cox GA. The evaluation of an ultrasound detector (UD) in the measurement of oro-facial dyskinesia. Int Clin Psychopharmacol 1987; 2:159-164.
57. Symington GR, Leonard DP, Shannon PJ, Vajda FJE. Sodium valproate in Huntington's disease. Am J Psychiatry 1978;135:352-354.
58. Leonard DP, Kidson, MA, Shannon PJ, Brown J. Double-blind trial of lithium carbonate and haloperidol in Huntington's chorea. Lancet 1974;2:1208-1209.
59. Bartzokis G, Wirshing WC, Hill MA, Cummings JL, Altshuler L, May PRA. Comparisons of electromechanical measures and observer ratings of tardive dyskinesia. Psychiatry Res 1989;27:193-198.
60. Wirshing WC, Cummings JL, Dencker SJ, May PRA. Electromechanical characteristics of tardive dyskinesia. J Neuropsychiatry Clin Neurosci 1991;3:10-17.
61. Buruma OJS, Kemp B, Roos RAC, Franzen JM, Velde van der EA. Quantification of choreatic movements by Doppler radar. Acta Neurol Scand 1982;66:363-368.
62. Falek A. Preclinical detection of Huntington's chorea. In: Barbeau A, Brunette J-R, eds. Progress in Neuro-genetics. Proceedings of the Second International Congress of Neurogenetics. Amsterdam: Exerpta Medica Foundation, 1976.
63. Fann WE, Stafford JR, Malone RL, Frost JD, Richman BW. Clinical research techniques in tardive dyskinesia. Am J Psychiatry 1977;34:759-762.
64. Buruma OJS, Roos RAC, Furnee EH, Antwerpen van G. Assessment of dyskinesia. In: Bruyn GW, Buruma OJS, Roos RAC, eds. Dyskinesia. Leiden: Boerhaave, 1984.
65. Denney D, Casey D. An objective method for measuring dyskinetic movements in tardive dyskinesia. Electroencephalogr Clin Neurophysiol 1975;38:645-646.
66. Chien CP, Jung K, Ross-Townsend A, Steams B. The measurement of persistent dyskinesia by piezoelectric recording and clinical rating scales. Psychopharmacol Bull 1977;13:34-36.
67. Nilsson FM, Hansen BL, Buchel C, Gattaz WF, Gerlach J. Digital movement analysis, a new objective method of measuring tardive dyskinesia and drug-induced parkinsonian tremor: acceptability, reliability and validity. Eur Arch Psychiatry Clin Neurosci 1996; 246:71-77.
68. Klawans HL, Rubowitz R. Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J Neurol Neurosurg Psychiatry 1974;27:941-947.
69. Hagell P, Widner H. Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale. Mov Disord 1999;14:448-455.